Clinical Trial Update: Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intermittent or continuous panitumumab plus FOLFIRI in RAS/B-RAF wild-type metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Panitumumab (panitumumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Colorectal Cancer Stage IV | Phase 2 | Status: COMPLETED